Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of
Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon
EGFR Mutations Only, Including L861Q, G719X, and/or S768I)